Effects of Angeliq and Prempro on Blood Pressure and Sodium Sensitivity in Postmenopausal Women With Prehypertension
Postmenopause, Hypertension, Pre-Hypertension
About this trial
This is an interventional treatment trial for Postmenopause focused on measuring Pre-Hypertension in Postmenopausal Women
Eligibility Criteria
Inclusion Criteria:
- Postmenopausal women 45 - 65 years old with prehypertension
Exclusion Criteria:
- Hormone therapy (estrogen/progestin)
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Active Comparator
0.5mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)
2.0mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)
1.5 mg MPA / 0.3 mg CEE (Prempro)
0.5 mg drospirenone/1.0 mg 17β-estradiol for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)
2.0 mg drospirenone/1.0 mg 17β-estradiol for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)
1.5 mg medroxyprogesterone acetate/0.3 mg conjugated equine estrogen for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)